BRIEF-Theratechnologies says 82.5 pct of patients achieved the primary endpoint in late-stage trial of HIV drug
May 24 (Reuters) - Theratechnologies
* Notified by partner of results for primary end point of phase iii trial with ibalizumab in patients with multi-drug resistant hiv-1
* Theratechnologies announces that 82.5% of patients achieved the primary endpoint in the phase iii ibalizumab trial Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
© Thomson Reuters 2017 All rights reserved.